Non Hodgkin Lymphoma Clinical Trial
Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies
Summary
This is a first-in-human phase 1 study of SYNCAR-001 + STK-009 in patients with CD19+ hematologic malignancies.
Full Description
SYNCAR-001 + STK-009 is a 2-component human orthogonal (ho) IL-2 receptor-ligand cell therapy consisting of (1) SYNCAR-001, a CD19-directed chimeric antigen receptor T cell (CAR-T) co-expressing an engineered IL-2 beta receptor (hoRb); and (2) STK-009, an engineered pegylated IL-2 cytokine (hoIL-2) selective for hoRb. The study will follow a 3+3 dose escalation design followed by a dose extension phase at the recommended phase 2 dose (RP2D)
Eligibility Criteria
Selected Inclusion Criteria:
Histologically confirmed relapsed/refractory hematologic malignancies, including Chronic Lymphocytic Lymphoma (CLL/SLL) and selected Non-Hodgkin's Lymphoma (NHL)
Prior or current documentation of CD19 expression or high likelihood of CD19 expression based on disease histology
No signs of symptoms of central nervous system (CNS) disease or detectable evidence of CNS or meningeal disease on magnetic resonance imaging (MRI) at the time of screening
Selected Exclusion Criteria:
Prior CD19 directed therapy including CD19 CARTs
Prior allogeneic hematopoietic stem cell transplant within 6 months of enrollment
Prior autologous hematopoietic stem cell transplant within 6 weeks of enrollment.
Presence of GVHD
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
How clear is this clinincal trial information?